41 results about "CD8A" patented technology

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The compositions and methods described herein can be used, for example, to determine the propensity of a patient to benefit from treatment with a PD-L1 axis binding antagonist and to treat such patients accordingly. Using the compositions and methods of the disclosure, a patient, such as a human cancer patient, may be determined to be likely to benefit from treatment with a PD-L1 axis binding antagonist if the patient exhibits an elevated pre-treatment expression level of one or more of CST7, NKG7, GZMH, MT-ND4, HLA-H, CCL5, CD8A, CMC1, CD8B, HCST, MT-CYB, MT-ND4L, KLRG1, MT-CO2, MT-ATP6, PLEK, CTSW, HLA-C, LYAR, LITAF, GZMB, KLRD1, FGFBP2, KLRC4-KLRK1, KLRK1, B2M, GZMA, ID2, CX3CR1, PRSS23, GNLY, PRF1, and PATL2. Exemplary PD-L1 axis binding antagonists that may be used in conjunction with the compositions and methods of the disclosure are PD-L1 binding antagonists, such as anti-PD-L1 antibodies and antigen-binding fragments thereof, including atezolizumab, as well as PD-1 binding antagonists, such as anti-PD-1 antibodies and antigen-binding fragments thereof.

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

The invention provides a c-Met-targeted single-chain antibody, a chimeric antigen receptor, a recombinant vector, a CAR-T cell and application, and belongs to the technical field of tumor treatment. The amino acid sequence of the single-chain antibody is shown as SEQ ID No.2; and the chimeric antigen receptor comprises a CD8a signal peptide, a Flag label, the single-chain antibody, a CD8a hinge region-transmembrane region, a 4-1BB functional region and a CD3 functional region which are connected in sequence. The c-Met-targeted chimeric antigen receptor can be highly and specifically combined with a c-Met antigen, T cells modified by the c-Met-targeted chimeric antigen receptor can efficiently kill c-Met high-expression tumor cells in a targeting manner, and relatively ideal curative effects are achieved in vivo and in vitro.

Fibronectin type III domain (FN3) specifically binding to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing FN3 domains, and related vectors, and detectably labeled FN3 domains Can be used in therapeutic and diagnostic applications.

The present invention discloses a human BCMA-specific chimeric antigen receptor (anti-BCMA scFv-CD8a-41BB-CD3ζ) and an application thereof. The chimeric antigen receptor consists of a single-chain antibody anti-BCMA scFv, a hinge region, a transmembrane region, and an intracellular region in tandem. The chimeric antigen receptor is used to modify human T lymphocytes, and the modified T lymphocytes are used for the prevention and treatment of surface BCMA positive tumors and the preparation of tumor drugs.

The invention belongs to the field of biotechnology, and specifically relates to a chimeric antigen receptor based on human mesothelin antibody, a lentiviral expression vector and applications thereof. The chimeric antigen receptor consists of human CD8a molecular signal peptide, human mesothelin The single-chain antibody of corticosteroid, the flexible fragment of human CD8a molecule, the transmembrane region and intracellular region of human CD28 molecule, the intracellular region of human 41BB molecule, and the intracellular region of human CD3z molecule are sequentially connected in series. The chimeric antigen receptor prepared by the present invention can target mesothelin and improve the therapeutic effect of CAR-T cells.